Hyperforin inhibits cancer invasion and metastasis

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6225-6232

  Donà, Massimo ^a   Dell'Aica, Isabella ^a   Pezzato, Elga ^a   Sartor, Luigi ^a   Calabrese, Morelia ^b   Della Barbera, Mila ^b   Donella Deana, Arianna ^a   Appendino, Giovanni ^c   Borsarini, Anna ^a   Caniato, Rosy ^a   Garbisa, Spiridione ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM DERIVATIVE; CATHEPSIN G; DICYCLOHEXYLAMMONIUM DERIVATIVE; GELATINASE A; GELATINASE B; HYPERFORIN; HYPERFORIN DICYCLOHEXYLAMMONIUM; LEUKOCYTE ELASTASE; MATRIX PROTEIN; MATRIX PROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEINASE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CANCER GROWTH; CANCER INVASION; CELL LINE; CLONOGENESIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; IC 50; MALE; METASTASIS; MOUSE; NONCOMPETITIVE INHIBITION; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOHEXYLAMINES; ENZYME ACTIVATION; FIBROSARCOMA; GELATINASES; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEUROBLASTOMA; PHLOROGLUCINOL; QUATERNARY AMMONIUM COMPOUNDS; SERINE ENDOPEPTIDASES; TERPENES;

EID: 4344652967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0280     Document Type: Article

References (44)

1. Barnes J, Anderson LA, Phillipson JD. St. John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001;53:583-600.
2. Mansky PJ, Straus SE. St. John's wort: more implications for cancer patients. J Natl Cancer Inst (Bethesda) 2002;94:1157-8.
3. Watkins RE, Maglich JM, Moore LB, et al. 2.1 Å crystal structure of human PXR in complex with the St, John's wort compound hyperforin. Biochemistry 2003;42: 1430-8.
4. Schempp CM, Pelz K, Wittmer A, Schöpf E, Simon JC. Antibacterial activity of hyperforin from Saint John's wort, against multiresistant Staphylococcus aureus and Gram-positive bacteria. Lancet 1999;353:2129.
5. Schempp CM, Winghofer B, Ludtke R, Simon-Haarhaus B, Schöpf E, Simon JC. Topical application of St. John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol 2000;142:979-84.
6. Schempp CM, Kirkin V, Simon-Haarhaus B, et al. Inhibition of tumor cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 2002;21:1242-50.
7. Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St. John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm 2003;56:121-32.
8. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.) 1980;284:67-8.
9. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y. Matrix metalloproteinase-9 (92 kDa gelatinase/lype IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci 1993;104:991-9.
10. Azzam HS, Arand G, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (Bethesda) 1993;85:1758-64.
11. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
12. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
13. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC) 2002;295:2387-92.
14. Wang ZY, Huang MT, Ho CT, et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1992;52:6657-65.
15. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature (Lond.) 1999;398:381.
16. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, Albini A. Tumor invasion: molecular shears inhibited by green tea. Nat Med 1999;5:1216.
17. Taniguchi S, Fujiki H, Kobayashi H, et al. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992;65:51-4.
18. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by green tea flavanol (-)epigallocatechin-3- gallate. Cancer (Phila.) 2001;91:822-32.
19. Demeule M, Brossard M, Page M, Gingras D, Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 2000;1478:51-60.
20. Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: phytofactor for hindering inflammation, emphysema and invasion. J Leuk Biol 2002;71:73-9.
21. Lambert JD, Lee M-J, Lu H, et al. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003;133:4172-7.
22. Biber A, Fisher H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31: 36-43.
23. Chatterjee SS, Erdelmeier C, Klessing K, Marmé D, Schächtele C. Stable hyperforin salts: method for producing them and their use in the treatment of Alzheimer's disease. PCT WO 99/41220, 1999 August 19.
24. Verotta L, Appendino G, Belloro Eet al. Synthesis and biological evaluation of Hyperforin analogues. Part I. Modification of the enolized cyclohexanedione moiety. J Nat Prod 2002;65:433-8.
25. Cervo L, Rozio M, Ekalle-Soppo CB, Guiso G, Morazzoni P, Caccia S. Role of Hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 2002;164:423-8.
26. Gimbrone MA Jr, Shefton EJ, Cruise SA. Isolation and primary culture of endothelial cells from human umbilical vessels. Tissue Culture Association Manual 1978;4: 813-8.
27. Foster BA, Gingrich JR., Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
28. Valduga G, Reddi E, Garbisa S, Jori G. Photosensitization of cells with different metastatic potentials by liposome-delivered Zn-(II)-phthalocyanine. Int J Cancer 1998;75:412-7.
29. Brown PD, Bloxidge RE, Anderson E, Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993;11:183-9.
30. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252-8.
31. Moon SK, Lee YC, Kim CH. Disialo ganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. J Biol Chem;2004 June 2 [epub ahead of print].
32. Westermarck J, Kähäri V-M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
33. Chung T-W, Lee Y-C, Kim C-H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERKs and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004 May 7 [epub ahead of print].
34. Brolis M, Gabetta N, Fuzzati R, Pace R, Panzeri F, Peterlongo F. Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high-performance liquid chromatography-UV absorbance detection of active constituents of Hypericum perforatum. J Chromatogr A 1998;825: 9-16.
35. Schempp CM, Simon JC. Use of hyperforin and derivatives thereof for inhibiting angiogenesis, and therapeutic use. PCT WO 03/EP4748, 2003 May 6.
36. Liang JC, Lin-Schiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of CDK inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)epigallocatechin-3- gallate. J Cell Biochem 1999;75:1-12.
37. Sugiura Y, Shimada H, Seeger RC, Laung WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998;58:2209-16.
38. Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999;80:764-72.
39. Stemlicht MD, Werb Z. Neutrophil elastase and cathepsin G. In: Kreis T, Vale R, editors. Extracellular matrix, anchor, and adhesion proteins, Oxford University Press: Oxford; 1999. p. 543-5.
40. Blackwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357:539-45.
41. Donà M, Dell'Aica I, Calabrese F, et al. Neutrophil restraint by green tea: inhibition of inflammation and associated angiogenesis and pulmonary fibrosis. J Immunol 2003;70:4335-41.
42. Albert D, Zündorf I, Dingermann T, Müller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002;64:1767-75.
43. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-8.
44. Marthijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst (Bethesda) 2002;94:1247-9.